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Abstract: Despite recent improvements in cancer treatment, with many of them being related to
foster antitumor immunity, tumor-related deaths continue to be high. Novel avenues are needed
to complement existing therapeutic strategies in oncology. Medical gas plasma technology recently
gained attention due to its antitumor activity. Gas plasmas act via the local deposition of a plethora
of reactive oxygen species (ROS) that promote the oxidative cancer cell death. The immunological
consequences of plasma-mediated tumor cell death are only poorly understood, however. To this end,
we exposed two prostate cancer cell lines (LNCaP, PC3) to gas plasma in vitro, and investigated the
immunomodulatory effects of the supernatants in as well as of direct co-culturing with two human
myeloid cell lines (THP-1, HL-60). After identifying the cytotoxic action of the kINPen plasma jet, the
supernatants of plasma-treated prostate cancer cells modulated myeloid cell-related mitochondrial
ROS production and their metabolic activity, proliferation, surface marker expression, and cytokine
release. Direct co-culture amplified differentiation-like surface marker expression in myeloid cells
and promoted their antitumor-toxicity in the gas plasma over the untreated control conditions. The
results suggest that gas plasma-derived ROS not only promote prostate cancer cell death but also
augment myeloid cell activity and cytotoxicity.
Keywords: HL-60; immunomodulation; kINPen; LNCaP; PC3; plasma medicine; reactive oxygen
species; ROS; THP-1
1. Introduction
Despite recent improvements in cancer treatment, with many of them being related to foster
antitumor immunity, tumor-related deaths continue to be high. With over 1.5 million new cases
worldwide in 2018 and a high mortality rate [1], this is also seen in prostate cancer patients. While
the 5-year survival rate of loco-regional prostate cancer is nearly 100%, it drops to 31% in the case of
tumor metastasis [2]. In the US, prostate-cancer related death ranks second in men behind lung cancer.
Standard treatment for loco-regional prostate cancer is surgery or radiation, while metastatic prostate
cancer is targeted using androgen deprivation therapy as first-line treatment, with docetaxel as an
emerging drug [3]. However, the disease is still fatal in many patients, exemplifying the need for novel
therapeutic avenues against prostate cancer.
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Medical gas plasma technology recently gained attention due to its antitumor activity against
many types of cancers [4–6]. Specifically, plasma was shown to inactivate, for instance, malignant
melanoma [7], squamous cell carcinoma [5,8], lung cancer [9], colon cancer [10], pancreatic cancer [11],
osteosarcoma [12], glioblastoma [13], and hepatocellular carcinoma [14]. The technology uses electrical
discharge to partially ionize a neutral gas, and is designed in a way that it promotes biomedical effects
in cells and tissues without thermal harm [15]. Instead, the gas plasmas act via the local deposition of a
plethora of reactive oxygen species (ROS) [16] that promote cancer cell death [17]. Previous studies
suggested that plasma-induced tumor toxicity also has an immunogenic component [18–20], leading
to antitumor immunity in vivo [21–23]. Specifically, it was observed that plasma treatment leads to an
increased expression of calreticulin, a protein that dictates the immunogenicity of cells [24]. In vivo,
plasma treatment not only limits tumor growth but also is associated with an increase in tumor-infiltrating
leukocytes [25,26]. Prostate cancer also has an immunological dimension [27], and especially myeloid
cells are frequently high-jacked by tumor cells to render them into tumor-promoting phenotypes [28].
To this end, we here investigated not only the cytotoxic potential of medical gas plasma technology
in targeting human prostate cancer cells but also the immunomodulatory consequences of the latter
towards human myeloid cells. Using both supernatant and co-culture assay systems, we identified an
augmentation of myeloid cell activity and cytotoxicity towards gas plasma-treated prostate cancer
cells in vitro.
2. Materials and Methods
2.1. Cell Culture
The prostate cancer cell lines LNCaP (ATCC, Manassas, VA, USA; ATCC CRL-1740) and PC3
(ATCC CRL-1435) as well as the myeloid cell lines THP-1 (ATCC TIB-202) and HL-60 (ATCC CCL-240)
were used in this study. The prostate cancer cell lines were retrieved from metastatic lesions, with LNCaP
as an androgen-sensitive cell line derived from a lymph node metastasis and the androgen-insensitive
PC3 cell line derived from bone metastasis. The cells were cultured in Roswell Park Memorial Institute
(RPMI) 1640 medium supplemented with 10% fetal bovine serum, 2% glutamine, and 1% penicillin
and streptomycin (all Sigma-Aldrich, Taufkirchen, Germany). Cells were sub-cultured twice or thrice
per week and maintained under standard culture conditions (37 ◦C, 5% CO2, and 95% humidity).
2.2. Gas Plasma Treatment of Tumor Cells
The atmospheric pressure plasma jet kINPen (neoplas tools, Greifswald, Germany) was operated
at 3.0 standard liters of argon per minute and 1.1 MHz. Quality control of the plasma generation was
done as previously described [29]. A thorough description of the physical principles of plasma jets was
given recently [30]. For cell growth kinetics, 3 × 104 (LNCaP) or 1 × 104 (PC3) cells in 500 µL of fully
supplemented cell culture medium were seeded into 24-well plates and exposed to different plasma
treatment times. For the generation of tumor cell culture supernatants, 2 × 105 cells in 500 µL of fully
supplemented cell culture medium were seeded into 24-well plates and exposed to plasma. In initial
experiments, argon gas only (plasma: off) treatment was used as a mock control. Argon is an inert gas
with no known direct biological effects.
2.3. Tumor Cell Supernatant Incubation of Myeloid Cells and Setup of Co-Culture Assays
Four hours after plasma treatment, tumor cell culture supernatants were collected, centrifuged at
1000× g for 5 min to discard residual cells and debris, and stored at −20 ◦C until use. For experiments,
80 µL of this supernatant was added to wells of a flat-bottom 96-well plate (Eppendorf, Hamburg,
Germany). To each well, 20 µL of a cell suspension containing 1 × 104 of either THP-1 or HL-60 cells
was added. The myeloid cells were incubated for up to 96 h. The Eppendorf 96-well plates have an
outer rim that was filled with deionized water to prevent excessive evaporation from the outer wells, as
observed with extensive culture durations. For the co-culture of prostate cancer and myeloid cells, the
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96-well plates were coated with 0.01% poly-l-lysine. 2.5 × 104 (LNCaP) or 1.25 × 104 (PC3) in 100 µL of
cell culture medium cells were labeled with trace violet (Thermo Fisher Scientific, Dreieich, Germany)
before being added to each well. The cells were exposed to the gas plasma and incubated for another
30 min in the incubator. Subsequently, 2.5 × 104 or 1.25 × 104 THP-1 or HL-60 cells were labeled with cell
trace red (Thermo Fisher Scientific, Dreieich, Germany) and added to the tumor cells together with sytox
green (Thermo Fisher Scientific, Dreieich, Germany) for the identification of terminally dead cells.
2.4. Cell Counting, Metabolic Activity, and Cell Viability
For the counting of cells in growth kinetic experiments, a CASY cell counter and analyzer
model TT (Roche Applied Science, Mannheim, Germany) with a 150 µm capillary was used. For
analyzing the metabolic activity of cells, resazurin (100 µM; Alfa Aesar, Haverhill, MA, USA) was
added. The non-fluorescent resazurin is converted intracellularly only in metabolically active cells
via an NADPH-dependent reduction to the fluorescent product resorufin. After 2 h of incubation,
resorufin fluorescence was quantified using a microplate reader (F200; Tecan, Männedorf, Switzerland)
at λex535 nm and λem590 nm. To determine the absolute number of viable myeloid cells, flow cytometry
(CytoFLEX S; Beckman-Coulter, Brea, CA, USA) was used. Live-dead discrimination was done by the
addition of 4′,6-diamidino-2-phenylindole (DAPI, 1 µM; Sigma-Aldrich, Taufkirchen, Germany), and
only live cells were gated for subsequent analysis.
2.5. Analysis of Reactive Oxygen Species (ROS), Oxidation, and Mitochondria
Hydrogen peroxide (H2O2) was quantified using the amplex ultra red (Thermo Fisher Scientific,
Dreieich, Germany) assay according to the manufacturer’s instructions as described in detail before [29].
To analyze the generation or deposition of ROS to the intracellular compartment, the myeloid cells
were stained with either chloromethyl 2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCF-DA,
1 µM; Thermo Fisher Scientific, Dreieich, Germany) converted intracellularly to the fluorescent
dichlorodihydrofluorescein (DCF) or 3′-(p-aminophenyl) fluorescein (APF, 1 µM; (Thermo Fisher
Scientific, Dreieich, Germany) before the addition of tumor cell culture supernatants to 2 × 104 labeled
myeloid cells per well. Subsequently, the mean fluorescent intensity (MFI) of the dyes in the cells was
analyzed by flow cytometry. To analyze the effect of the supernatants on the mitochondrial membrane
potential, the myeloid cells were labeled with mitotracker orange (MTO, 1 µM; Thermo Fisher Scientific,
Dreieich, Germany) before the addition of the tumor cell culture supernatants, and the MFI of MTO
was analyzed using flow cytometry. In all assays, DAPI was used to gate on the live-cell population
only for analysis of oxidation and mitochondria.
2.6. Cell Surface Marker Analysis
To analyze the expression of several myeloid cell surface markers simultaneously, multicolor flow
cytometry was used. At 96 h, the myeloid cells were harvested into 96-well v-bottom plates using
accutase. The cells were washed and stained against a selection of the monoclonal antibodies used in
this study for targeting several cell surface receptors (Table 1). DAPI was added to quantify the MFI of
each marker only in the live-cell population. After 15 min of incubation at room temperature in the
dark, the cells were washed and acquired using a CytoFLEX S cytometer (Beckman-Coulter, Brea, CA,
USA). The same procedure was performed for both the monoculture and co-culture assay systems.
Discrimination of myeloid cells from tumor cells was done based on CD55 vs. HLA-ABC expression
(THP-1 cells had higher baseline intensities for both parameters compared to prostate cancer cells)
for THP-1 cells, and based on forward-scatter (tumor cells had higher signal intensities) vs. CD32
(HL-60 cells had higher signal intensities) for HL-60 cells.
2.7. Quantification of Chemokines and Cytokines
The quantification of chemokines and cytokines was performed in supernatants derived from
prostate cancer cells (4 h after plasma treatment), myeloid cells incubated with and without supernatants
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of prostate cancer cells (at 96 h), and co-cultures of myeloid cells with cancer cells (at 96 h). To this end,
a 12-target, bead-based sandwich immunoassay (LegendPLEX; BioLegend, London, UK) was utilized.
Quantification was done against an internal standard for chemokine (C-C motif) ligand 17 (CCL17),
chemokine (C-X-C motif) ligand 1 (CXCL1), CXCL10, interferon-gamma (IFNγ), interleukin 1-beta
(IL1β), IL6, IL8, IL10, IL12p70, tumor growth factor-beta (TGFβ), tumor necrosis factor-alpha (TNFα),
and vascular endothelial growth factor (VEGF).















2.8. Live-Cell High Content Imaging
Prostate cancer cells were labeled with cell trace violet (1 µM; Thermo Fisher Scientific, Dreieich,
Germany) and cultured together with cell trace red-labeled myeloid cells (1 µM; Thermo Fisher
Scientific, Dreieich, Germany) as described above for co-culture. Sytox green (0.1 µM; Thermo Fisher
Scientific, Dreieich, Germany) was added for the detection of terminally dead cells. Live-cell imaging
was performed using an Operetta CLS (PerkinElmer, Hamburg, Germany) high content imaging device
equipped with a CO2 and temperature control chamber. Protection from evaporation was ensured
since the rim of the 96-well plate was filled with deionized water. Imaging was performed at 24 h,
48 h, 72 h, and 96 h post plasma exposure using a 20× (NA 0.4) air objective (Zeiss, Jena, Germany)
for 25 fields of view per well, time point, and channel. Channels were brightfield, digital phase
contrast, cell trace violet (λex405 nm, λem465 nm), sytox green (λex475 nm, λem525 nm), and cell trace
red (λex630 nm, λem680 nm). A total of 25,000 images were acquired and analyzed in this study.
2.9. Statistical and Software Analysis
Statistical analysis was performed using prism 8.4 (Graphpad Software, San Diego, CA, USA).
Either t-test, ratio-paired t-test, or one-way analysis of variances with Dunnett posthoc testing was
used. The level of significance is indicated as follows: p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***).
At least three independent experiments with several technical replicates each were done for each
assay. Flow cytometric analysis and fluorescence compensation were done using Kaluza analysis
2.1.1 (Beckman-Coulter, Brea, CA, USA). About 2000 individual measurements were analyzed in the
present study. Quantitative image analysis was performed using Harmony 4.9 (PerkinElmer, Hamburg,
Germany). The cells were segmented based on their digital phase-contrast signal, and the type of cell
was determined by using a threshold on relative signal intensities from cell trace violet or cell trace red
for prostate cancer and myeloid cells, respectively.
3. Results
3.1. The Plasma Jet Treatment Decelerated Prostate Cancer Cell Growth
Medical gas plasma treatment using the kINPen atmospheric pressure plasma jet was performed
against prostate cancer cells in vitro. Two experimental schemes were used to identify the potential
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effects of that treatment in prostate cancer cells on myeloid cells (Figure 1a). In the first setup, prostate
cancer cells were exposed to the plasma, and the cell culture supernatants were collected after four
hours and added to myeloid cells. At 1 h, immediate effects such as ROS production and mitochondrial
activity were determined. At 24 h, the metabolic activity and cell proliferation of the myeloid cells
were investigated. At 96 h, the cell surface marker expression profile and cytokine release were
assessed. In the direct co-culture approach, the prostate cancer cells were exposed to the plasma,
and myeloid cells were added 1 h later. The co-cultures were imaged at 24 h, 48 h, 72 h, and 96 h,
with an additional investigation of the cell surface marker profile of myeloid cells and the cytokine
release in the supernatants of the co-cultures at 96 h. An image of the plasma treatment procedure
is shown in Figure 1b. Based on previous studies, it was hypothesized that the plasma treatment
decelerates tumor cell growth. Investigating the impact on the metabolic activity of the cancer cells
4 h after plasma treatment, the treatment led to a significant reduction in both prostate cancer cell
lines investigated (Figure 1c). The plasma labeling denotes cells that were treated with the gas plasma
directly. The argon control indicates conditions where the inert argon gas was not ignited into plasma
but instead was merely blown onto the cell suspension as a mock treatment to exclude any biological
effects of the noble gas alone. Similar to other plasma jets, the kINPen generates ROS in the plasma gas
phase that subsequently diffuse into the treated liquid [31]. From there, the species further diffuse
to cells [16] with some of the species possibly accumulating in the cytosol, as has been suggested for
H2O2 passing through aquaporin channels in the membrane [32]. As the purpose was to investigate
the immunomodulatory potential of supernatants from the untreated and plasma-treated prostate
cancer cells, we also investigate residual ROS in these suspensions. Only a minor presence of ROS was
observed in the plasma-treated LNCaP cultures 1 h after exposure, while residual ROS were absent for
plasma-treated PC3 cells at 1 h (Figure 1d). At 4 h after plasma treatment, supernatants of the prostate
cancer cells were collected and used for subsequent experiments with myeloid cells. Altogether,
plasma treatment decelerated prostate cancer cell growth, and the majority of plasma-derived ROS
have reacted with the cancer cells.
3.2. Prostate Cancer Cell Supernatants Affected the Intracellular Oxidative Milieu and Metabolic Activity of
Myeloid Cells
The myeloid cell lines THP-1 and HL-60 were incubated with regular cell culture medium,
supernatants from untreated prostate cancer cells, or supernatants from plasma-treated prostate cancer
cells. Many cellular processes are subject to redox control, and we investigated the intracellular
oxidative milieu of the myeloid cells using the redox-sensitive dyes DCF and APF that accumulate in
the cytosol of cells upon staining. DCF is a pan-ROS sensor [33], while a certain degree of specificity
towards three types of ROS (hypochlorous acid, peroxynitrite, and hydroxyl radical) is attributed
to APF [34]. In THP-1 cells, the plasma-treated supernatants did not change DCF (Figure 2a) but
APF intensities, indicative of more intracellular ROS (Figure 2b). The difference was significant
when compared against both the use of untreated cancer cell supernatants and medium control only.
Mitochondria can be a source of intracellular ROS following response to a stimulus. To this end,
the mitochondrial membrane potential was investigated (Figure 2c) and a significant decrease was
observed in response to incubation with all types of prostate cancer cell supernatants when compared
against the medium control (Figure 2d). In HL-60 cells, and similarly to THP-1, DCF did not show
significant changes in fluorescence for any of the conditions investigated (Figure 2e). In contrast to
THP-1 cells, this was also the case for APF in HL-60 cells (Figure 2f). For mitochondria, however,
a decrease in the membrane potential was observed (Figure 2g), which was significant following
incubation with all types of prostate cancer cell supernatants when compared against the medium
control (Figure 2h). These data suggest that the tumor cell supernatants are sensed and recognized by
the myeloid cells, as evident in the mitochondria response and partially also in the ROS production.
Mitochondrial activity is closely linked to metabolic activity. To this end, the effect of the cancer cell
supernatants on the metabolic activity and proliferation of myeloid cells was investigated 24 h after
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incubation. For THP-1 cells, a significant increase in metabolic activity was observed (Figure 2i), while
cell numbers differed only to a minor extent from that of the cell culture medium control (Figure 2j).
The metabolic activity per cell was significantly increased for supernatants from PC3 cells (Figure 2k).
For HL-60 cells, a decrease in metabolic activity was found, which was significant for supernatants
from LNCaP cells (Figure 2l). The absolute cell numbers indicative of changes in proliferation did not
vary to a great extent (Figure 2m), which in sum led to a significantly decreased metabolic activity per
cell for supernatants from LNCaP on HL-60 cells (Figure 2n). In summary, it can be concluded for
the metabolic activity assays that the supernatants of the prostate cancer cells had an impact on the
myeloid cell activity, especially in THP-1 cells. The plasma treatment, however, did not provoke effects
much different from those observed with supernatants from untreated prostate cancer cells.
Figure 1. The kINPen gas plasma treatment decelerated the growth of prostate cancer cells. (a) outline
of the experimental procedures and time lines performed in this study; (b) image of the kINPen
atmospheric pressure argon plasma jet treating cells in a well of a 24-well plate; (c) metabolic activity of
LNCaP and PC3 cells 4 h after kINPen plasma treatment; (d) residual reactive oxygen species (ROS)
(H2O2) 1 h after kINPen plasma treatment of LNCaP and PC3 cells as well as fully supplemented cell
culture medium compared to untreated medium control. Data are presented as mean ± SEM of three
independent experiments. Statistical analysis was performed using one-way analysis of variances
with posthoc testing after Dunnett. The level of significance is indicated as follows: p < 0.001 (***).
ctrl = control; ar = inert argon gas mock treatment (plasma off).
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Figure 2. Oxidation and metabolic activity of myeloid cells following exposure to supernatants of
kINPen plasma-treated prostate cancer cells. (a,b) normalized mean fluorescent intensity of THP-1
cells stained with (a) DCF and (b) APF, two dyes indicating intracellular redox changes, and exposed
to control cell culture medium (dashed line), untreated supernatants of LNCaP or PC3 cells (ctrl),
or supernatants of plasma-treated LNCaP or PC3 cells (plasma); (c,d) overlay histogram (c) and
quantification (d) of THP-1 cells stained with mitotracker orange (MTO) and exposed to control cell
culture medium (dashed line), untreated supernatants of LNCaP or PC3 cells (ctrl), or supernatants of
plasma-treated LNCaP or PC3 cells (plasma); (e,f) normalized mean fluorescent intensity of HL-60
cells stained with (e) DCF and (f) APF, and exposed to control cell culture medium (dashed line),
untreated supernatants of LNCaP or PC3 cells (ctrl), or supernatants of plasma-treated LNCaP or
PC3 cells (plasma); (g,h) overlay histogram (g) and quantification (h) of HL-60 cells stained with
mitotracker orange (MTO) and exposed to control cell culture medium (dashed line), untreated
supernatants of LNCaP or PC3 cells (ctrl), or supernatants of plasma-treated LNCaP or PC3 cells
(plasma); (i–k) metabolic activity (i) and absolute cell counts (j) as well as ratio of metabolic activity
over cell counts (k) of THP-1 cells exposed to control cell culture medium (dashed line), untreated
supernatants of LNCaP or PC3 cells (ctrl), or supernatants of plasma-treated LNCaP or PC3 cells
(plasma) at 24 h; (l–n) metabolic activity (l) and absolute cell counts (m) as well as ratio of metabolic
activity over cell counts (n) of HL-60 cells exposed to control cell culture medium (dashed line),
untreated supernatants of LNCaP or PC3 cells (ctrl), or supernatants of plasma-treated LNCaP or PC3
cells (plasma) at 24 h. Data are presented as mean of three to five independent experiments with several
technical replicates each. Statistical analysis was performed using ratio-paired t-test. ctrl = control. The
level of significance is indicated as follows: p < 0.05 (*) or (#).
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3.3. Plasma-Treated Prostate Cancer Cell Supernatants Promoted Immunomodulation in Myeloid Cells
The activity and differentiation of immune cells can be judged based on their expression of surface
molecules and the release of pro and anti-inflammatory mediators such as chemokines and cytokines.
Tumor cells secrete immunomodulatory mediators into the liquid environment. It was hypothesized
that plasma treatment changes the composition and concentration of these mediators, which would
lead to a different myeloid cell phenotype. To this end, we investigated both the surface receptor
expression profile and chemokine and cytokine release of myeloid cells cultured with supernatants
of untreated or plasma-treated prostate cancer cells at 96 h. Representative overlay flow cytometry
histograms illustrate the distribution of a selection of surface receptor staining intensities (Figure 3a).
For THP-1 cells, there was a significant increase observed with supernatants of plasma-treated over
untreated prostate cancer cells for the cell surface markers CD11b, CD11c, and CD45RA (Figure 3c),
pointing to increased activation of the cells. Other significant changes observed were a decrease
for CD55, an increase in CD69, an increase in CD163, a decrease in CD271, and an increase in both
cell size and granularity, while the expression of HLA-ABC was unchanged. Most changes were
observed for supernatants of LNCaP (8 out of 10 markers), while significant changes with PC3 cell
supernatants were less prominent (2 out of 10 markers). For HL-60 cells, incubation with supernatants
of plasma-treated prostate cancer cells increased cell size and granularity but not the expression of
CD11b, CD11c, CD14, CD32, and CD 71 (Figure 3c). For P2Y2, a significant increase was observed for
plasma-treated LNCaP cells and their supernatants. In general, the markers investigated are indicators
of myeloid cell activation and differentiation, and the effect of the supernatants was more pronounced
in THP-1 compared to HL-60 cells.
To elucidate the immunomodulatory potential of the supernatants further, 12 different chemokines
and cytokines were quantified in the prostate cancer cell as well as myeloid cell supernatants (Figure 4).
This included CCL17 (Figure 4a), CXCL1 (Figure 4b), CXCL10 (Figure 4c), IFNγ (Figure 4d), IL1β
(Figure 4e), IL6 (Figure 4f), IL8 (Figure 4g), IL10 (Figure 4h), IL12p70 (Figure 4i), TGFβ (Figure 4j),
TNFα (Figure 4k), and VEGF (Figure 4l). For LNCaP, only IL6, IL1β, and VEGF were detectable, while
for PC3 cells, CXCL1, CXCL10, and IL8 were also found. Plasma treatment significantly decreased
the levels of all targets released from PC3 cells, while for LNCaP, a decrease in IL8 and VEGF, and an
increase in IL6 was observed. VEGF is a tumor-promoting factor [35], and its decrease with plasma
exposure points to a potentially beneficial effect. For THP-1 and HL-60 cells alone without tumor cell
supernatants, only IL6, IL8, TGFβ, and VEGF were found. For the supernatants of plasma-treated vs.
control prostate cancer cells alone (not added to myeloid cells), a significant decrease was found for IL6
and VEGF. The same was found for HL-60 cells, with other significant decreases observed for CXCL1
and IL8. Notably, there was no significant difference for supernatants of LNCaP cells incubated on
myeloid cells. This is in line with the surface marker expression data for HL-60 but not THP-1 cells,
with the latter showing a marked modulation that, however, was not reflected in the chemokine and
cytokine spectrum.
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Figure 3. The cell surface marker profiles of myeloid cells following exposure to supernatants of
kINPen plasma-treated prostate cancer cells. (a) representative overlay histograms of the flow cytometry
analysis; (b) normalized mean fluorescent intensities at 96 h of CD11b, CD11c, CD45RA, CD55, CD69,
CD163, CD271, HLA-ABC, forward scatter, and side scatter of THP-1 cells exposed to untreated
supernatants of LNCaP or PC3 cells (ctrl, dashed line) or supernatants of plasma-treated LNCaP or PC3
cells; (c) normalized mean fluorescent intensities at 96 h of forward scatter, side scatter, CD11b, CD11c,
CD14, CD16, CD32, CD71, and P2Y2 of HL-60 cells exposed to untreated supernatants of LNCaP or
PC3 cells (ctrl, dashed line) or supernatants of plasma-treated LNCaP or PC3 cells. Data are presented
as violin plots with median of three to five independent experiments with several technical replicates
each. Statistical analysis was performed using ratio-paired t-test. The level of significance is indicated
as follows: p < 0.05 (*) and p < 0.01 (**).
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Figure 4. The cytokine profiles of myeloid cells following exposure to supernatants of kINPen
plasma-treated prostate cancer cells. (a–l) quantification of the levels of CCL17 (a), CXCL1 (b), CXCL10
(c), IFNγ (d), IL1β (e), IL6 (f), IL8 (g), IL10 (h), IL12p70 (i), TGFβ (j), TNFα (k), and vascular endothelial
growth factor (VEGF) (l) in untreated and kINPen plasma-treated prostate cancer cells (collected at 4 h)
as well as THP-1 and HL-60 cell culture supernatants at 96 h with or without the addition of untreated
or kINPen plasma-treated tumor cell culture supernatants. Data show the mean + S.E. of data from
supernatants retrieved from at least three independent experiments. Statistical analysis was performed
using ratio-paired t-test. The level of significance is indicated as follows: p < 0.05 (*) and p < 0.01 (**).
ctrl = control; Pl = plasma; LOD = limit of detection.
3.4. Plasma-Treated Prostate Cancer Cells Promoted Myeloid Cell Differentiation and Tumor-Toxic Activity
The supernatants of untreated and plasma-treated prostate cancer cells led to a modulation of
intracellular ROS, metabolic activity, cell surface marker expression, and cytokine release in myeloid
cells. The next question was to understand how the direct cell–cell interaction between plasma-treated
tumor and myeloid cells induced immunomodulation in myeloid cells. Representative overlay flow
cytometry histograms illustrate the distribution of selected signal intensities (Figure 5a). A range of
cell surface receptors was investigated in THP-1 cells, including CD11b, CD11c, CD45RA, CD55, CD69,
CD163, HLA-ABC, as well as the percentage of viable cells, and cell size and granularity (Figure 5b).
Except for CD11c and granularity, a significant increase was observed for all markers for one or both of
the prostate cancer cell co-cultures investigated. This was even more pronounced in HL-60 cells, where
all of the studied parameters were significantly regulated in one or both of the prostate cancer cell
co-cultures. This included cell viability, size, and granularity as well as expression of CD11b, CD14,
CD16, CD32, CD71, and P2Y2 (Figure 5c). This suggested that the plasma-induced prostate cancer cell
death was driving differentiation-like responses in human myeloid as compared to those observed in
co-cultures with untreated prostate cancer cells.
To investigate the immunomodulatory potential of the secretory products of plasma-treated
prostate cancer cells on myeloid cells, chemokine, and cytokine quantification of the same targets
as above (Figure 4) was performed (Figure 6). For THP-1 prostate cancer co-cultures, a significant
regulation of CXCL1, CXCL10, IL8, and VEGF was observed with plasma treatment. For HL-60,
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CXCL1, IL8, and VEGF were significantly regulated. With the exception of IL6 but not CXL10 being
significantly regulated (Figure 4), the co-culture results were mostly congruent with those of the
supernatant cultures except that the concentrations identified were several-fold higher.
Figure 5. The cell surface marker profiles of myeloid cells co-cultured with kINPen plasma-treated
prostate cancer cells. (a) representative overlay histograms of the flow cytometry analysis; (b) normalized
mean fluorescent intensities at 96 h of CD11b, CD11c, CD45RA, CD55, CD69, CD163, HLA-ABC, viable
cells, forward scatter, and side scatter of THP-1 cells cultured with either untreated (ctrl, dashed line)
or plasma-treated LNCaP or PC3 cells; (c) normalized mean fluorescent intensities at 96 h of forward
scatter, side scatter, CD11b, CD14, CD16, CD32, CD71, P2Y2, and viable HL-60 cells cultured with either
untreated (ctrl, dashed line) or plasma-treated LNCaP or PC3 cells. Data are presented as violin plots
and median of three to five independent experiments with several technical replicates each. Statistical
analysis was performed using ratio-paired t-test. The level of significance is indicated as follows:
p < 0.05 (*).
Plasma-treated prostate cancer cells co-cultured with myeloid cells spurred the expression
of activation markers and modulated the cytokine release profiles. The next question was how
these observed findings related to the tumor-toxic behavior of the myeloid cells. To this end, we
utilized differential fluorescent staining and live-cell imaging to investigate several parameters
using algorithm-driven quantitative image analysis. For THP-1 cells co-cultured with untreated or
plasma-treated prostate cancer cells (Figure 7a), a significant increase in dead tumor cells was observed
for LNCaP and in tendency also for PC3 cells (Figure 7b). Plasma-induced cell death is usually found
within the first 24 h of incubation, but the number of dead cells in co-cultures was elevated throughout
the time course up to 96 h, arguing for an auto-amplification of the tumor-toxic effects by THP-1 cells.
This is supported by the enhanced phagocytosis index of THP-1 cells taking up prostate cancer cells
(Figure 7c), suggesting clearance of dead prostate cancer cells. To investigate the effect of plasma
treatment on the cell–cell interaction between the myeloid and prostate cancer cells, the mean distance
between myeloid cells and cancer cells was calculated using algorithm-driven quantitative analysis.
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A decrease was observed (Figure 7d), indicating that the myeloid cells migrated closer to the tumor
cells if the latter had been plasma-treated. We also calculated the THP-1 over the prostate cancer
cell ratio to model growth and survival behavior in the co-cultures over the 96 h (Figure 7e). An
increase for the THP-1 to tumor cell ratio was observed for the plasma treatment conditions that
was significant for the 72 h time point. The same set of experiments was performed for HL-60 cells
(Figure 8a). Here, a continuous elevation of dead tumor cells was less pronounced as compared to
the results obtained for THP-1 cells, but significantly elevated cell death was observed for PC3 cells
(Figure 8b). Tumor cell phagocytosis was increased in tendency in all conditions, being significant only
for 72 h in co-cultures with PC3 cells (Figure 8c). The HL-60 to tumor cell distance was unchanged for
LNCaP but significantly decreased for PC3 cells, pointing to enhanced migratory activity of HL-60
to PC3 cells. Lastly, the HL-60 to tumor cell ratio was decreased for HL-60-LNCaP co-cultures in the
plasma conditions (Figure 8d), suggesting a growth advantage of the cancer cells over the myeloid
cells in this setting. For plasma-treated PC3 cells, however, a significant increase of that ratio was
observed (Figure 8e). From the results and the amplitude of changes observed, it can be concluded
that THP-1 cells actively responded to plasma-treated LNCaP cells and mostly also to PC3 cells in
terms of favorable repression of tumor cell growth and survival. By contrast, HL-60 cells seemed not
to propagate the cytotoxic plasma effects when co-cultured with plasma-treated LNCaP cells, while
responses to PC3 prostate cancer cells were more pronounced.
Figure 6. The cytokine profiles of myeloid cells co-cultured with kINPen plasma-treated prostate cancer
cells. (a–m) quantification of the levels of CCL17 (a), CXCL1 (b), CXCL10 (c), IFNγ (d), IL1β (e), IL6 (f),
IL8 (g), IL10 (h), IL12p70 (i), TGFβ (j), TNFα (k), and VEGF (l) retrieved after 96 h from supernatants
of THP-1 and HL-60 cell culture supernatants co-cultured with untreated or kINPen plasma-treated
prostate cancer cells. Data show the mean + S.E. of data from supernatants retrieved from at least three
independent experiments. Statistical analysis was performed using ratio-paired t-test. The level of
significance is indicated as follows: p < 0.01 (**) and p < 0.001 (***). ctrl = control; Pl = plasma; LOD =
limit of detection.
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Figure 7. Quantitative image analysis of THP-1 cells co-cultured with plasma-treated prostate cancer
cells. (a) prostate cancer cells were labeled with cell trace violet (blue) and were left untreated or
exposed to the plasma, followed by addition of cell trace red (red) labeled THP-1 cells one hour later
with sytox green (green) serving as dead cell marker; (b–e) algorithm-driven quantitative image analysis
per image area of the total number of dead tumor cells per well (b), tumor cell phagocytosis (c), mean
distance (in µm) between THP-1 cells and tumor cells (d), and the THP-1/tumor cell ratio (e). Data are
presented as mean + S.E. of three independent experiments. Statistical analysis was performed using
t-test. The level of significance is indicated as follows: p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***). Scale
bar is 50 µm. c = control; p = plasma; ns = not significant.
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Figure 8. Quantitative image analysis of HL-60 cells co-cultured with plasma-treated prostate cancer
cells. (a) prostate cancer cells were labeled with cell trace violet (blue) and were left untreated or
exposed to the plasma, followed by addition of cell trace red (red) labeled HL-60 cells one hour later
with sytox green (green) serving as dead cell marker; (b–e) algorithm-driven quantitative image analysis
per image area of the total number of dead tumor cells per well (b), tumor cell phagocytosis (c), mean
distance (in µm) between HL-60 cells and tumor cells (d), and the HL-60/tumor cell ratio (e). Data are
presented as mean + S.E. of three independent experiments. Statistical analysis was performed using
t-test. The level of significance is indicated as follows: p < 0.05 (*) and p < 0.01 (**). Scale bar is 50 µm.
c = control; p = plasma; ns = not significant.
4. Discussion
The aim of this study was to investigate the immunomodulatory effects of two human
plasma-treated prostate cancer cell lines towards two human myeloid cell lines in vitro. In comparison
to untreated prostate cancer cells, the plasma treatment provoked significant changes in surface marker
expression, cytokine release, and cytotoxic activity of the myeloid cells towards the tumor cells.
Supernatants of and co-cultures with cancer and myeloid cells modulated the surface marker
expression and cytokine release upon plasma treatment. Nearly all markers investigated were
significantly changed in at least one plasma-condition. Similar to CD11b [36,37], CD11c is associated
with myeloid cell maturation in both cell types [38,39]. Interestingly, CD11c expression is regulated
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via AP-1 [40], a transcription factor we have recently described to respond to plasma-derived redox
modulation in THP-1 cells [41]. Similarly, de novo CD69 expression is induced during the early
activation of myeloid cells [42]. An increase in HLA-ABC expression, and cell size and granularity
has been described for myeloid cell activation as well [39,43,44]. In terms of polarization, our marker
panel was not designed for a detailed view on this aspect. We found CD163 to be increased in THP-1
cells, a marker commonly associated with M2 macrophages [45] but also found in inflammatory
macrophages [46]. For HL-60 cells, a marked upregulation of CD14, CD32, and CD71 was determined
only in co-culture experiments but not in the supernatant conditions related to plasma treatment. CD14,
part of the LPS receptor, is associated with activation and maturation of HL-60 cells [47,48]. The same is
true for CD32 [49,50], an Fcγ receptor. The transferrin receptor CD71, however, usually is internalized
in activated HL-60 cells [51], leading to a decrease in surface receptor expression. Nevertheless, CD71
was also reported to be associated with macrophage development [52,53]. Although not all markers
were regulated in each of the settings to a similar extent, a clear tendency towards activation was seen
for both the supernatant and co-culture experiments. This suggests that plasma-induced cytotoxicity in
prostate cancer cells leads to myeloid cell activation and differentiation, which often is also associated
with changes in the secretion profile of cytokines [54].
Cytokine release reflects the inflammatory milieu generated by cells. In the supernatant
experiments, a significant decrease was observed for CXCL1, IL6, IL8, and VEGF in the plasma
conditions. Both IL6 and IL8 are markers of activation and differentiation in myeloid cells, at least
when using mitogens as stimulating agents [55]. Along similar lines, an increase in CXCL1 is found
in M1 macrophages differentiated with PMA [56]. Increased VEGF is observed in M2 polarized
macrophages [57]. This suggests that activation and differentiation were lower with plasma treatment
of tumor cells. However, our data also show that the levels of CXCL1, IL6, IL8, and VEGF for myeloid
cells were similar to that of the tumor cells alone. Hence, it can be speculated that the contribution of
the myeloid cells to the cytokine levels was not pronounced in the supernatant experiments, despite
the significant changes in surface marker expression. One reason for that might be the low initial
cell number used, and the ability of the cells to internalize extracellular chemokines and cytokines
produced during the 96 h-period of incubation. The unchanged levels of TGFβ and the significantly
decreased levels of VEGF need to be emphasized because both are potent tumor-promoting effectors in
the tumor microenvironment [58,59]. This was also observed in our co-culture experiments, pointing
to a potentially beneficial effect of the plasma treatment. In contrast to the supernatant experiment,
a marked increase for CXCL10 was observed in the plasma conditions. CXCL10 is released upon
tumor-toxic M1 macrophage polarization [60]. IL8 also was significantly increased in three of the
four plasma-conditions investigated in the co-culture system, and the chemokine is associated with
chemo-attraction of phagocytes and increased inflammation. Several other pro-inflammatory targets
leading to potentially tumor-toxic effects, such as CCL17, IFNγ, IL1β, and IL6, were increased in
tendency. It was previously reported that myeloid cell-derived IL1β abrogated proliferation of LNCaP
cells [61]. Elevated IL6 levels may also be a consequence of a feedback loop between cancer and
myeloid cells, as least for LNCaP and THP-1 cells [62]. Our data on only little induction of IL1β and
IL6 in myeloid cells by prostate cancer cell-derived supernatants are in line with previous findings [63].
A noticeable increase in TNFα, as identified in a previous study being the principal tumor-toxic agent
of macrophages [64], was not observed, however. In general, it is still a matter of debate of how
macrophages exert cytotoxic effects against cancer cells. Besides the reported TNFα [63], activated
M1 but not M2 macrophages were previously found to produce family 18 chitinases that pose potent
tumor-toxic acitivity [65]. GM-CSF was also noted to enhance the tumor toxic activity of macrophages
in vitro [66], while others reported direct antibody-dependent cytotoxicity and phagocytosis of tumor
cells as mechanisms of action [67].
Nevertheless, we observed cytotoxic effects in prostate cancer cells co-cultured with myeloid cells
that extended much further to the initial plasma treatment at 0 h. This was supported by our findings
on increased tumor cell uptake and migration towards tumor cells in the plasma conditions. Enhanced
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tumor-toxicity in co-culture systems was reported before with activated vs. non-activated THP-1
cells [68]. In our study, we have several indices of macrophage activation through direct interaction
with plasma-treated prostate cancer cells and their secretory products. At least in THP-1 cells, which
showed greater tumor-toxic properties compared to HL-60 cells, this was underlined by an increase in
intracellular ROS, a hallmark of monocyte activation [69] and macrophage differentiation [70]. Both
myeloid cell lines showed a significant decrease in the mitochondrial membrane potential, which
is associated with increased ROS production [71]. Whether the differences observed with DCF and
APF point to differences in ROS entities and functional consequences in myeloid cells remains an
open question. Notwithstanding, especially the HL-60-LNCaP co-culture showed the least cytotoxic
activity on the cancer cells following plasma exposure. From the cell surface and cytokine data, it
seems that this condition did not promote HL-60 differentiation and activation to such an extent as
observed for PC3 cells, for instance. CD11b, CD14, CD32, CD71, and side scatter were markedly
less increased in co-culture with LNCaP compared to PC3 cells, which supports this view. CD16, a
marker of differentiation in HL-60 cells [72], even was significantly decreased in HL-60 cells co-cultured
with plasma-treated LNCaP over untreated LNCaP cells. Moreover, this co-culture condition was the
only one among the four myeloid cell–tumor cell co-cultures that showed a non-significant increase
instead of a significant decrease in VEGF. VEGF can polarize myeloid cells towards a non-inflammatory
phenotype [73], which might explain the lower killing activity of HL-60 cells in co-culture with the
LNCaP cells.
Our study focused on myeloid cell activation and inflammatory markers in response to
plasma-killed prostate cancer cells. Monocyte-to-macrophage differentiation and polarization, mainly
to tumor-associated macrophages (TAM), is a clinical trait of prostate cancer associated with poor
prognosis and tumor recurrence [74,75]. Mechanistically, tumors constantly attract myeloid cells from
the bloodstream via several secreted factors, such as VEGF, which in turn drives pro-tumorigenic
macrophage polarization [76,77]. Plasma treatment decreased VEGF levels in prostate cancer cell
supernatants and co-cultures with myeloid cells. This suggests that plasma treatment might be able
to modulate the tumor microenvironment in disfavor of tumor growth. This question should be
targeted in future studies using more complex prostate tumor models and primary myeloid cells, both
being a limitation of our study. Nevertheless, THP-1 cells are a good model for studying monocyte
activation and differentiation, and compared genereally well with primary monocytes and especially
M1 polarization in various previous studies [78–83]. Another question is how plasma treatment
might be applied clinically in prostate cancer patients as already done in a fraction of head and neck
cancer patients [84,85]. One option would be to expose to resection-margins after surgery to the gas
plasma. This way, micro-metastasis that often lead to tumor recurrence might be decreased. This
might also be achieved using plasma-treated liquids that were recently proposed to have anticancer
properties as well [86,87]. Such liquid might also be injected directly into the tumor, using guided
ultrasound microinjection. Tumor-toxic injections with plasma-treated liquids have been recently
demonstrated in vivo using a model of pancreatic cancer [88]. Finally, another timely question is
whether plasma treatment might be able to revert chemotherapeutic resistance, but apart from first
studies on drug-transporter expression in cancer cells after plasma treatment [89,90], such studies are
yet awaited to come.
5. Conclusions
Plasma-treated prostate cancer cells were superior in activating myeloid cells as compared to the
tumor cell supernatants. This suggests that not only soluble factors but also direct cell–cell contact to
be a factor promoting the cytotoxicity and differentiation of tumor-toxic myeloid cells. The promising
nature of these findings in terms of gas plasma treatment of prostate cancer needs to be further
evaluated in experimental disease models in the future.
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